<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02835404</url>
  </required_header>
  <id_info>
    <org_study_id>2012012</org_study_id>
    <nct_id>NCT02835404</nct_id>
  </id_info>
  <brief_title>Pelvic External Combined With 252-Cf Neutron Intracavitary Radiotherapy With or Without Platinum in Treating Advanced Cervical Cancer</brief_title>
  <official_title>A Randomized, Open Label, Single Centre Clinical Trial of Pelvic External Radiotherapy Combined With 252-Cf Neutron Intracavitary Brachytherapy With or Without Platinum in Treatment of Local Advanced Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</source>
  <brief_summary>
    <textblock>
      The objective of this study was to evaluate the efficacy and complication of the treatment of
      pelvic external combined with 252-Cf neutron intracavitary radiotherapy with or without
      platinum in local advanced cervical cancer patients in the short and long term.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute toxicity events</measure>
    <time_frame>Week 5 of Radiation Therapy (RT)</time_frame>
    <description>chemo-related toxicity as measured by CTCAE v. 4.0, radiation-related toxicity as measured by RTOG/EORTC criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-trem toxicity events</measure>
    <time_frame>through study completion, an average of 5 year</time_frame>
    <description>chemo-related toxicity as measured by CTCAE v. 4.0, radiation-related toxicity as measured by RTOG/EORTC criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2 Years Overall survial Rate</measure>
    <time_frame>2 years</time_frame>
    <description>chemo-related toxicity as measured by CTCAE v. 4.0, radiation-related toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 Years Overall survial Rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5 Years Overall survial Rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>through study completion, an average of 3 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survial (OS)</measure>
    <time_frame>through study completion, an average of 5 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Complications</condition>
  <arm_group>
    <arm_group_label>Concurrent radiochemotherapy Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concurrent radiochemotherapy with Nedaplatin Pelvic External Radiotherapy: patients received 20 Gy2.0/f, for 25-27f with 8mv-X rays (SSD) 252-Cf Neutron Intracavitary Brachytherapy: total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations; Chemotherapy: Nedaplatin(NDP) 30-40mg/m2 iv., on day1, 4weeks as one cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients received Radiotherapy only Pelvic External Radiotherapy: patients received 20 Gy2.0/f, for 25-27f (SSD)with 8mv-X Linear Accelerator SSD 252-Cf Neutron Intracavitary Brachytherapy: total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nedaplatin</intervention_name>
    <description>Chemotherapy: Nedaplatin(NDP) 30-40mg/m2 iv., on day1, 4weeks as one cycle</description>
    <arm_group_label>Concurrent radiochemotherapy Group</arm_group_label>
    <other_name>NDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Pelvic External Radiotherapy</intervention_name>
    <description>patients received 20 Gy2.0/f, for 25-27f (SSD)with 8mv-X rays (SSD)</description>
    <arm_group_label>Concurrent radiochemotherapy Group</arm_group_label>
    <arm_group_label>Radiotherapy Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>252-Cf Neutron Intracavitary Brachytherapy</intervention_name>
    <description>total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations</description>
    <arm_group_label>Concurrent radiochemotherapy Group</arm_group_label>
    <arm_group_label>Radiotherapy Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. To be aged from 18 (including 18) to 65 (including 65), female patient;

          -  2. Expected survival ≥6 months

          -  3. Pathologically proven diagnosis of squamous carcinoma or adenocarcinoma of the
             cervix, according to FIGO(International Federation of Gynecology and Obstetrics)
             staging, appropriate stage for protocol entry, including IIA2, IIB,IIIA,IIIB;

          -  4. No patients with distant metastases;

          -  5. Measurable target lesions (satisfying the criteria in RECIST 1.1);

          -  6. ECOG PS status of 0-2;

          -  7. No prior treatment;

          -  8. No

          -  9. No surgery

          -  10. Major organ function has to meet the following criteria:

               1. Bilirubin &lt;1.5 times the upper limit of normal (ULN)

               2. ALT , AST and APL≤2.5 × ULN

               3. NEUT≥2.0 × 10^9 / L

               4. PLT ≥ 100 × 10^9 / L

               5. HB≥60g/L

               6. Serum Cr and urea nitrogen ≤ 1.5 × ULN

          -  11. Favorable cardiac functions, no patients with myocardial infarction within half a
             year, hypertension and coronary disease are well-controlled.

        Exclusion Criteria:

          -  1. Serious heart disease, pulmonary disease, hepatic disease, , renal disease and
             metabolic disease, or with electrolyte disturbance;

          -  2. Allergic to platinum;

          -  3. Rejecte to join the study in other conditions.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Lei, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xin Lei, M.D</last_name>
    <phone>+86 023-68757176</phone>
    <email>dpxinlei@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Lei, M.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2016</study_first_submitted>
  <study_first_submitted_qc>July 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2016</study_first_posted>
  <last_update_submitted>July 13, 2016</last_update_submitted>
  <last_update_submitted_qc>July 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</investigator_affiliation>
    <investigator_full_name>Xin Lei, M.D.Prof</investigator_full_name>
    <investigator_title>M.D, Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nedaplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

